Recent Finacing
Recent Raise
Neurovance is a clinical-stage neuroscience company developing EB-1020 SR, a norepinephrine- and dopamine-preferring nonstimulant reuptake inhibitor for adult ADHD, with Phase 1 completed and Phase 2a data.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
